In Chile, as in other Latin American countries, a significant portion of clinical trials fail to meet their objectives due to logistical shortcomings. According to data presented by the Chilean Society of Clinical Pharmacology (2023), about 25% of clinical studies suspended in the country are due to operational and recruitment issues.
Consequences of poor clinical execution:
• Loss of international funding.
• Damage to the medical center’s reputation.
• Delays in delivering innovative treatments.
• Failure to collect useful data for national clinical practice.
Advantages of having support like Gestalt Medical’s:
• Coordination with public and private healthcare networks.
• Strategic territorial recruitment.
• Sample logistics and regulatory documentation.
• Monitoring and traceability of the entire study.
References:
1. Sociedad Chilena de Farmacología Clínica – Reunión Anual 2023
2. ANAMED – Normativa de Ensayos Clínicos, ISP 2022
3. FDA (2020). “Operational Barriers to Clinical Trials”
4. PAHO (2023). “Investigación Clínica en América Latina”
5. Universidad de Chile – Unidad de Ensayos Clínicos 2023
English 
Spanish